These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22263712)

  • 1. Buprenorphine-naloxone maintenance following release from jail.
    Lee JD; Grossman E; Truncali A; Rotrosen J; Rosenblum A; Magura S; Gourevitch MN
    Subst Abus; 2012; 33(1):40-7. PubMed ID: 22263712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
    Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
    JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
    Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N
    J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 6. Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?
    Curtiss FR
    J Manag Care Pharm; 2008 Mar; 14(2):195-7. PubMed ID: 18331121
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.
    Apelt SM; Scherbaum N; Gölz J; Backmund M; Soyka M
    Pharmacopsychiatry; 2013 May; 46(3):94-107. PubMed ID: 23293011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine treatment in an urban community health center: what to expect.
    Cunningham C; Giovanniello A; Sacajiu G; Whitley S; Mund P; Beil R; Sohler N
    Fam Med; 2008; 40(7):500-6. PubMed ID: 18928077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    Am J Addict; 2013; 22(3):212-7. PubMed ID: 23617861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
    Hard B
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.